Álvarez-Fernández, Sonia
Andrade-González, Nelson
Simal, Patricia
Matias-Guiu, Jordi A.
Gómez-Escalonilla, Carlos
Rodriguez-Jimenez, Roberto
Stiles, Bryan J.
Lahera, Guillermo
Funding for this research was provided by:
Instituto de Salud Carlos III (INT20/00079, PI19/00766)
Article History
Received: 3 August 2022
Accepted: 26 December 2022
First Online: 12 January 2023
Declarations
:
: The study was performed in compliance with the Helsinki Declaration for research on humans and was approved by the Ethical Committee for Clinical Research of the University Hospital San Carlos of Madrid (Spain). All patients signed an informed consent form.
: Not applicable.
: Dr. Álvarez-Fernández, Dr. Andrade-González, Dr. Simal, Dr. Matias-Guiu, Dr. Gómez-Escalonilla, and Mr. Stiles declares no competing interests. Dr. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), CIBERSAM, Madrid Regional Government, Janssen-Cilag, Otsuka-Lundbeck, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, and Angelini Pharma. Dr. Lahera has been a consultant to or has received honoraria or grants from Janssen-Cilag, Otsuka-Lundbeck, Angelini Pharma, Lilly, Astra-Zeneca, CIBERSAM, and Instituto de Salud Carlos III.